Skip to main content
ACoP 2024 Main banner
Final Program


Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

C3B - Leveraging quantitative models to design and develop the next generation of multi-specific T-Cell engager molecules

Tuesday, November 12, 2024
2:00 PM – 3:30 PM MST
Location: Sonoran Sky Ballroom 1 - 4

Disclosure(s):
Iraj Hosseini, Distinguished Scientist/Group Head/Pharmacology Team Leader: Roche: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Alexander Kulesza, PhD: ABLATOM SAS: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); CreativeQuantum GmbH: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); ESQlabs GmbH: Employment (Ongoing)

Presentations:

  • 2:00 PM – 2:30 PM MST
    Development of a Quantitative Systems Pharmacology Model to Support the Clinical Development of T cell Redirecting Bi- and Tri-specific Antibodies for Patients with Relapsed/Refractory Multiple Myeloma

    Speaker: Jin Niu, PhD (she/her/hers) – J&J

  • 2:30 PM – 3:00 PM MST
    Utilizing platform QSP models for later phase trial design and dose selection

    Speaker: Brian Schmidt

  • 3:00 PM – 3:30 PM MST
    Bispecific T-cell engagers: From receptor to systems’ level modeling to rationalize dose-effect relationships

    Speaker: Alexander Kulesza, PhD (he/him/his) – Systems Pharmacology Lead